Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk
Clinical trial NCT05672537 · UNKNOWN
Trial details
- NCT number
- NCT05672537
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-01-20
- Primary completion
- 2024-12-31
- Enrollment
- 70
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.